NPS CEO gives insight into orphan drug pricing

01/7/2013 | Forbes

When pricing a new biologic drug, developers consider medical value, direct and indirect costs, market size and insurers' willingness to pay, NPS Pharmaceuticals CEO Francois Nader said. In the case of drugs to treat rare diseases, such as NPS' Gattex, NPS will give grants to rare-disease organizations that will help patients pay, and the company will offer copay assistance.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA